title: Mechanisms of regulation of PFKFB expression in pancreatic and gastric cancer cells.
abstract: Enzymes 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 and -4 (PFKFB-3 and PFKFB-4) play a significant role in the regulation of glycolysis in cancer cells as well as its proliferation and survival. The expression of these mRNAs is increased in malignant tumors and strongly induced in different cancer cell lines by hypoxia inducible factor (HIF) through active HIF binding sites in promoter region of PFKFB-4 and PFKFB-3 genes. Moreover, the expression and hypoxia responsibility of PFKFB-4 and PFKFB-3 was also shown for pancreatic (Panc1, PSN-1, and MIA PaCa-2) as well as gastric (MKN45 and NUGC3) cancer cells. At the same time, their basal expression level and hypoxia responsiveness vary in the different cells studied: the highest level of PFKFB-4 protein expression was found in NUGC3 gastric cancer cell line and lowest in Panc1 cells, with a stronger response to hypoxia in the pancreatic cancer cell line. Overexpression of different PFKFB in pancreatic and gastric cancer cells under hypoxic condition is correlated with enhanced expression of vascular endothelial growth factor (VEGF) and Glut1 mRNA as well as with increased level of HIF-1α protein. Increased expression of different PFKFB genes was also demonstrated in gastric, lung, breast, and colon cancers as compared to corresponding non-malignant tissue counterparts from the same patients, being more robust in the breast and lung tumors. Moreover, induction of PFKFB-4 mRNA expression in the breast and lung cancers is stronger than PFKFB-3 mRNA. The levels of both PFKFB-4 and PFKFB-3 proteins in non-malignant gastric and colon tissues were more pronounced than in the non-malignant breast and lung tissues. It is interesting to note that Panc1 and PSN-1 cells transfected with dominant/negative PFKFB-3 (dnPFKFB-3) showed a lower level of endogenous PFKFB-3, PFKFB-4, and VEGF mRNA expressions as well as a decreased proliferation rate of these cells. Moreover, a similar effect had dnPFKFB-4. In conclusion, there is strong evidence that PFKFB-4 and PFKFB-3 isoenzymes are induced under hypoxia in pancreatic and other cancer cell lines, are overexpressed in gastric, colon, lung, and breast malignant tumors and undergo changes in their metabolism that contribute to the proliferation and survival of cancer cells. Thus, targeting these PFKFB may therefore present new therapeutic opportunities.
authors.affiliation: Oleksandr H Minchenko, Dmytro O Minchenko, Department of Molecular Biology, Palladin Institute of Biochemistry, Kiev 01601, Ukraine.
authors.forename: Oleksandr H
authors.initials: OH
authors.lastname: Minchenko
authors.affiliation: Oleksandr H Minchenko, Dmytro O Minchenko, Department of Molecular Biology, Palladin Institute of Biochemistry, Kiev 01601, Ukraine.
authors.forename: Katsuya
authors.initials: K
authors.lastname: Tsuchihara
authors.affiliation: Oleksandr H Minchenko, Dmytro O Minchenko, Department of Molecular Biology, Palladin Institute of Biochemistry, Kiev 01601, Ukraine.
authors.forename: Dmytro O
authors.initials: DO
authors.lastname: Minchenko
authors.affiliation: Oleksandr H Minchenko, Dmytro O Minchenko, Department of Molecular Biology, Palladin Institute of Biochemistry, Kiev 01601, Ukraine.
authors.forename: Andreas
authors.initials: A
authors.lastname: Bikfalvi
authors.affiliation: Oleksandr H Minchenko, Dmytro O Minchenko, Department of Molecular Biology, Palladin Institute of Biochemistry, Kiev 01601, Ukraine.
authors.forename: Hiroyasu
authors.initials: H
authors.lastname: Esumi
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D049109:Cell Proliferation; D002470:Cell Survival; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D058990:Molecular Targeted Therapy; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000235:genetics / Q000473:pathology; D025481:Phosphofructokinase-2 / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism; D015398:Signal Transduction; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000235:genetics / Q000473:pathology; D059016:Tumor Microenvironment
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D004791:Enzyme Inhibitors; C506672:PFKFB4 protein, human; D012333:RNA, Messenger; C107345:PFKFB3 protein, human; D025481:Phosphofructokinase-2
keywords: 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3; 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-4; Gastric cancer; Hypoxia; Hypoxia inducible factor; Lung cancer; MKN45; NUGC3; PST-1; Panc1